Table 2.
Effects of Varenicline vs. Placebo on Neurocognitive Outcomes at Baseline and Day 13.
| Measure | Mean (SD) at: | Drug effecta | |||
|---|---|---|---|---|---|
| Baseline | Varenicline | Placebo | F | p | |
| CPT true positivesb | 57.20 (5.26) | 59.22 (1.39) | 58.73 (1.56) | 7.28 | .009 |
| N-Back true positivesb | 49.97 (7.04) | 52.34 (4.42) | 52.36 (4.03) | 0.001 | .98 |
| CET true positivesb | 41.87 (11.79) | 41.97 (12.80) | 40.78 (11.00) | 0.38 | .54 |
| CPT correct RTc | 485.7 (50.04) | 489.8 (50.53) | 499.1 (53.40) | 5.86 | .018 |
| N-Back correct RTc | 559.9 (139.9) | 546.1 (129.2) | 575.0 (140.7) | 11.08 | .001 |
| CET correct RTc | 2609.0 (1025.3) | 2541.2 (1173.5) | 2380.2 (793.6) | 1.21 | .28 |
a
Effect of medication (varenicline vs. placebo) in mixed effects model controlling for treatment order, sex, baseline score, cigarettes per day at baseline, and (in N-back models) working memory load (0- vs. 1- vs. 2- vs. 3-back).
b
Number of correct responses.
c
Median reaction time (milliseconds) for correct responses.